Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 14/20 | 0.62 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.62 |
| ▸ | HTR6 | P50406 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2026034 | 0.85 | HCRTR2 (0.73) | HCRTR1HCRTR2HTR6 | |
| SCHEMBL2130318 | 0.84 | HCRTR1 (0.61) | HCRTR1HCRTR2HTR6CYP3A4CYP2D6 | |
| SCHEMBL13465048 | 0.83 | HTR6 (0.55) | HCRTR1HCRTR2HTR6CYP3A4CYP2D6 | |
| SCHEMBL2023628 | 0.80 | HTR6 (0.62) | HCRTR1HCRTR2HTR6CYP3A4CYP2D6 | |
| SCHEMBL15339797 | 0.78 | HTR6 (0.50) | HCRTR1HCRTR2HTR6CYP3A4CYP2D6 | |
| SCHEMBL2027104 | 0.77 | HTR6 (0.49) | HCRTR1HCRTR2HTR6CYP3A4CYP2D6 | |
| SCHEMBL2027115 | 0.77 | HCRTR2 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL2024994 | 0.73 | HCRTR2 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL15435624 | 0.70 | HTR6 (0.63) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL2022489 | 0.69 | HCRTR2 (1.00) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516439-B1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| EP-2516439-B1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| EP-2516439-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| WO-2011076747-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076747-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | REN, PKD1, NR3C2 | HCRTR1 3548/4885HCRTR2 3205/4885HTR6 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.